Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae279 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Sara Abou Azar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Chicago Medicine, Chicago, IL 60637, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Neoplasm Recurrence, Local, Carcinoma, Neuroendocrine, Thyroidectomy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Context
Medullary thyroid cancer (MTC) has a historic recurrence rate up to 50%, and surgery remains the only cure.
Objective
This study aims to assess factors related to recurrence and metastatic spread in MTC.
Methods
Retrospective chart review was performed from 1990 to 2023 at a single specialized tertiary care referral center. Descriptive analysis and regression models were used for analysis. Sixty-eight patients with MTC, who underwent surgery, were included and the main outcome measure was recurrence.
Results
Median age at diagnosis was 54.9 years (42.2-64.1), 65% (n = 44) females. Lymph node and distant metastases were found in 24% (n = 16) and 4% (n = 3), respectively. RET mutations were present in 52% (n = 35): MTC risk levels were highest 6%, high 7%, and moderate 39%. Median tumor size was 1.9 cm (1.2-3.2) and median preoperative calcitonin was 504.4 pg/mL (133.2-1833.8). Total thyroidectomy (TT) was performed in 10 patients, TT + central neck dissection (CND) in 28, and TT + CND + lateral neck dissection (LND) in 25. On final pathology, 40% had positive central nodes and 25% had positive lateral nodes. Recurrence was 22%, median follow-up 4.7 years (1.2-28.0). Male gender (hazard ratio [HR] 5.81, P = .021), positive lateral neck nodes (HR 8.10, P = .011), and high/highest MTC risk level RET mutations (HR 8.66, P = .004) were significantly associated with recurrence. Preoperative calcitonin >2175 pg/mL was a strong predictor for distant metastasis (area under the curve [AUC] 0.893) and a good predictor for lateral neck disease (AUC 0.706). Extent of surgery was not significantly associated with recurrence (P = .634).
Conclusion
One of 4 patients undergoing surgery for MTC will recur. Risk factors associated with recurrence are male gender, lateral lymph node metastasis, and high/highest MTC risk level mutations, but not necessarily surgery type. Preoperative calcitonin >2175 pg/mL is suggestive of advanced disease and should prompt further evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Chicago Medicine, Chicago, IL 60637, USA.
ORCID-Profile: Sara Abou Azar
Zitieren
APA
Abou Azar, S., Tobias, J., Applewhite, M., Angelos, P., & Keutgen, X. M. (2024). Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae279
Vancouver
Abou Azar S, Tobias J, Applewhite M, Angelos P, Keutgen XM. Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae279
BibTeX
@article{AbouAzar2024,
author = {Abou Azar, Sara and Tobias, Joseph and Applewhite, Megan and Angelos, Peter and Keutgen, Xavier M},
title = {Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae279}
}
EUVIMED